R&D Insights: How Perrigo Company plc and Viridian Therapeutics, Inc. Allocate Funds

R&D Spending: A Tale of Two Companies

In the ever-evolving landscape of pharmaceuticals and biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Perrigo Company plc and Viridian Therapeutics, Inc. offer a fascinating study in contrasts over the past decade.

From 2014 to 2023, Perrigo consistently allocated substantial resources to R&D, peaking in 2018 with a 33% increase from 2014. However, a notable decline of 44% was observed by 2023, reflecting strategic shifts or market challenges. In contrast, Viridian's R&D investment skyrocketed, growing over 500 times from 2014 to 2023, underscoring its aggressive push into new therapeutic areas.

This divergence highlights the dynamic strategies companies employ to navigate the competitive biotech sector. As investors and stakeholders, understanding these trends is crucial for making informed decisions in a rapidly changing industry.